Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Sanofi ( (SNY) ) is now available.
In June 2025, Sanofi announced that its investigational drug riliprubart received orphan drug designation from the US FDA for treating antibody-mediated rejection in solid organ transplantation, highlighting a significant unmet need in transplant medicine. Additionally, riliprubart was granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy, reinforcing Sanofi’s commitment to addressing rare diseases and enhancing its position in the biopharmaceutical industry.
The most recent analyst rating on (SNY) stock is a Hold with a $67.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Neutral.
Sanofi’s overall stock score reflects strong financial performance and positive earnings call highlights, including robust sales growth and strategic initiatives. However, technical analysis indicates bearish momentum, and cash flow weaknesses along with market uncertainties slightly temper the outlook.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is an R&D driven, AI-powered biopharma company focused on improving lives through innovative medicines and vaccines. With a deep understanding of the immune system, Sanofi aims to address urgent healthcare challenges and is listed on EURONEXT and NASDAQ.
Average Trading Volume: 2,676,493
Technical Sentiment Signal: Buy
Current Market Cap: $119.5B
Learn more about SNY stock on TipRanks’ Stock Analysis page.